Hematological Cancer Consortium (HCC) is an initiative to establish cooperative group data in hematological malignancies in India. There is an increasingly felt need to establish good cooperative group data in hematological malignancies in India. This is required for us to move forward in developing evidence based and locally relevant treatment protocols and guidelines, rather than just modifying international one’s. In the long run this will also evolve into a forum to discuss recent advances and their relevance in our country / region and also to develop cooperative prospective collaborative trials.
The primary goal is to aggregate data that will in turn facilitate changes in a scientifically rational way based on the available data. In the long run it is anticipated that HCC will run investigator initiated prospective collaborative clinical trials addressing regionally relevant questions and evaluating cost effective treatment strategies. Studies will include all aspects of hematological cancers including but not limited to basic science, diagnostic tests, monitoring, therapeutic interventions, costs and long term effects. The studies and questions will be driven by participating members of HCC.
The major participants will be physicians dealing with hematological cancers from participating centers. However, nurses, allied health care providers, basic scientists from any organization, long term cancer survivors, members of pharmaceutical industry, well-wishers and anyone with an interest in the broad vision of improving medical care and access for patients with hematological cancers is welcome to be a members of HCC.
Currently, HCC has 14 leading cancer centers as institutional partner across the country; we look forward to expanding the HCC network in the near future to include any institution that is committed to the vision of HCC. The strength of any organization is only as dependent on enthusiasm of its members and we invite each of you to be active participants in this ambitious venture.
Hematological Cancer Consortium (HCC) is intended to be a multi-center collaborative academic organization to improve knowledge, standardize cost-effective treatment strategies and promote regionally relevant research in hematological cancers.
The Managing Committee is the Governing body of the Society. There are seven members in the committee. The office bearers are the President, Vice President, Secretary and Treasurer. The President is the head of the Society and has the responsibility to preside over the Annual General Meeting, Special General Meeting and Managing Committee meetings and to participate in all other activities of the Society.
The Society has an Advisory Board and an Executive Committee. The Advisory Board works closely and supports the Managing Committee.
The Executive Committee with the Managing Committee has a collective responsibility for the operation of the society. The role of executive committee members is to:
Dr. Vikram Mathews
Dr. L. Jeyaseelan
Dr. Manju Sengar
Dr. Girish Chinnaswamy
Dr. Sathya Subramani
Mr. Nihal Kaviratne
Dr. Tapan Kumar Saikia
Dr. Anuradha Monga
Army Research and Referral Centre, New Delhi
All India Institute of Medical Sciences (AIIMS), New Delhi
Cancer Institute Adyar (WIA), Chennai
MD. Dm professor Department of Clinical Haematology, Haemato-Oncology
Professor of Clinical Hematology Department of Clinical Hematology Gauhati Medical College and Hospital, Guwahati
Kolkata Institute Of Haematology & Transfusion Medicine, Kolkata
Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh
Rajiv Gandhi Cancer Institute And Research Centre, New Delhi
Regional Cancer Center, Jawaharlal Institute Of Postgraduate Medical Education & Research (JIPMER), Puducherry
Kidwai Cancer Institute, Bangalore
Tata Memorial Centre (TMC), Mumbai
Christian Medical College (CMC), Vellore